Researchers at Stanford University, in collaboration with scientists at the German Cancer Institute, have shown for the first ...

From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full ...

Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with the highest relaxivity, in comparison to other availab ...

Revvity reports that it will unveil the VivoJect™ image-guided injection system at the AACR Annual Meeting in Chicago later this week. Paired with the Vega™ automated preclinical ultrasound system, ...

Breast cancer remains one of the most prevalent cancers worldwide, accounting for 11.7 per cent of all cancer cases. In India, it is a leading cause of cancer-related deaths among […] ...

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...